...
首页> 外文期刊>藥學雜誌 >Necessity of Personalized Initial Loading Dose Calculation of Teicoplanin by Clinical Pharmacist -Examination of the Utility of Using Systemic Inflammatory Response Syndrome Score-
【24h】

Necessity of Personalized Initial Loading Dose Calculation of Teicoplanin by Clinical Pharmacist -Examination of the Utility of Using Systemic Inflammatory Response Syndrome Score-

机译:临床药剂师对临床药剂师的个性化初始装载剂量计算的必要性 - 使用全身性炎症反应综合征分数的效用 -

获取原文
获取原文并翻译 | 示例

摘要

When teicoplanin (TEIC) is injected at the maintenance dose, a long period is required for achievement of the target plasma trough concentration because of its long elimination half-life. An initial loading dose is necessary for rapid achievement of an effective plasma trough concentration. Thus, we proposed that it is necessary for a pharmacist determine the initial loading dose of TEIC to reach an effective plasma trough concentration rapidly after its administration to a patient. In the present study, we evaluated the effectiveness of initial loading dose determination by pharmacists and physicians by comparing the achievement rate of target plasma trough concentrations (>15 mu g/mL) and expression of adverse effects. Among 61 patients, 34 were treated according to an initial loading dose determined by a pharmacist (pharmacist intervention) and 27 were treated according to the treating physician's discretion (non-pharmacist intervention). The achievement rate of target concentrations was 91.2% (plasma trough concentration 23.3 +/- 5.3 mu g/mL) in the pharmacist intervention group and 25.9% (plasma trough concentration 14.0 +/- 5.9 mu g/mL) in the non-pharmacist intervention group. There was no difference in the incidence of adverse effects between the two groups. Also, we found that systemic inflammatory response syndrome (SIRS) may have a correlation with plasma trough concentrations of TEIC. We suggest that the SIRS score could become a means way of determining initial loading dose. These findings suggest that it is potentially effective for a pharmacist to determine this initial dose in order to rapidly achieve the target plasma trough concentration of TEIC.
机译:当在维护剂量注入滴定蛋白(TEIC)时,由于其长期消除半衰期,需要长时间来实现目标等离子体槽浓度。初始加载剂量是快速实现有效等离子体槽浓度所必需的。因此,我们提出了药剂师需要在给予患者的施用后迅速地确定初始装载剂量以迅速达到有效的血浆槽浓度。在本研究中,我们通过比较靶血浆槽浓度(>15μg/ ml)的成就率和不良反应的表达来评估药剂师和医生初始装载剂量测定的有效性。在61名患者中,根据药剂师(药剂师干预)确定的初始装载剂量,根据治疗医生的自由裁量权(非药剂师干预),治疗34例。药剂师干预组的目标浓度的成就率为91.2%(血浆槽浓度23.3 +/-5.3μg/ ml),非药剂师中的25.9%(血浆槽浓度14.0 +/-5.9μg/ ml)干预组。两组之间不利影响的发生率没有差异。此外,我们发现全身性炎症反应综合征(SIRS)可以与菲律的血浆槽浓度相关。我们认为SIRS评分可能成为确定初始装载剂量的方法。这些发现表明,药剂师确定该初始剂量潜在有效,以便快速实现Teic的靶血浆槽浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号